Cingulate Inc.

Contributing Author

Recent Articles by Cingulate Inc.

May-20	Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD CING GlobeNewswire
May-14	FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 CING GlobeNewswire
May-08	Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets CING GlobeNewswire